TuHURA Biosciences Inc Total Liabilities
TuHURA Biosciences Inc total liabilities. Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has total liabilities worth $13.25 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HURA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of TuHURA Biosciences Inc (2014–2026)
Total liabilities of TuHURA Biosciences Inc from 2014 to 2026. This chart illustrates how TuHURA Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
TuHURA Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of TuHURA Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Maywood Acquisition Corp. 2 Class A Ordinary Share
NASDAQ:MYX
|
USA | $165.57K |
|
GBM Resources Ltd
AU:GBZ
|
Australia | AU$22.09 Million |
|
Lavras Gold Corp
V:LGC
|
Canada | CA$1.55 Million |
|
Lippo General Insurance Tbk
JK:LPGI
|
Indonesia | Rp2.43 Trillion |
|
Nien Hsing Textile Co Ltd
TW:1451
|
Taiwan | NT$1.48 Billion |
|
Daishin Securities Co Ltd Pref 2
KO:003547
|
Korea | ₩38.04 Trillion |
|
John Hancock Investors Closed Fund
NYSE:JHI
|
USA | $91.36 Million |
|
Qilian International Holding Group Limited
NASDAQ:BGM
|
USA | $36.57 Million |
Liability Composition Analysis (2014–2026)
This chart breaks down TuHURA Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HURA total asset value.
Liquidity & Leverage Metrics
TuHURA Biosciences Inc Total Liabilities Ratios Explained
TuHURA Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TuHURA Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TuHURA Biosciences Inc (2014–2026)
The table below shows the annual total liabilities of TuHURA Biosciences Inc from 2014 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $6.42 Million | +19.51% |
| 2025-06-30 | $5.37 Million | -9.25% |
| 2024-06-30 | $5.92 Million | +104.67% |
| 2023-06-30 | $2.89 Million | -59.54% |
| 2022-06-30 | $7.15 Million | +141.39% |
| 2021-06-30 | $2.96 Million | +10.73% |
| 2020-06-30 | $2.67 Million | +29.24% |
| 2019-06-30 | $2.07 Million | +26.23% |
| 2018-06-30 | $1.64 Million | +23.05% |
| 2017-06-30 | $1.33 Million | -10.99% |
| 2016-06-30 | $1.50 Million | -55.93% |
| 2015-06-30 | $3.40 Million | -33.87% |
| 2014-06-30 | $5.14 Million | -- |
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more